We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Test as Accurate as Lumbar Punctures for Detecting Alzheimer’s

By LabMedica International staff writers
Posted on 25 Jan 2024

Individuals with Alzheimer’s disease often exhibit accumulations of amyloid and tau proteins in their brains, key indicators of the condition. More...

Typically, Alzheimer’s diagnosis is based on symptoms like cognitive and memory issues. However, only a small percentage (2%) of those diagnosed with dementia undergo ‘gold standard’ diagnostic methods such as PET scans or lumbar punctures. With the advent of novel Alzheimer’s therapies, enhancing diagnostic accuracy has become increasingly crucial. Now, findings from a study indicate that a commercial blood test might be able to identify Alzheimer’s disease as effectively as standard lumbar punctures. This test specifically detects ‘p-tau217’, a variant of the tau protein, which is a primary marker of Alzheimer’s.

This new study led by researchers at the University of Gothenburg (Mölndal, Sweden) demonstrated that blood levels of p-tau217 correlate with the levels of amyloid and tau proteins identified in brain scans and lumbar punctures. This discovery holds significant promise for transforming the diagnostic process for suspected Alzheimer’s patients. Notably, the study utilized a threshold for categorizing individuals into those likely or unlikely to have Alzheimer’s, and an intermediate group requiring further assessment through conventional methods like lumbar punctures or PET scans. By applying this blood test approach, researchers anticipate a substantial reduction, by approximately 80%, in the need for these more invasive follow-up tests.

However, several questions remain unresolved. There is a need for a more comprehensive understanding of how these blood tests perform in everyday clinical settings, particularly among diverse patient groups. Additionally, like new medical treatments, these blood tests must undergo regulatory approval before they can be integrated into healthcare practice. People need a quick and accurate diagnosis, which will “ultimately bring us closer towards a cure for dementia” said Dr. Sheona Scales, Director of Research at Alzheimer’s Research UK. “In the past year, we have seen incredible progress in the development of blood-based Alzheimer’s tests. And as we see more and more different types of tests becoming available, studies like this are key to understanding which are most accurate.”

Related Links:
University of Gothenburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.